Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. - Wikidata - awgldk - TriplyDB

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

http://www.wikidata.org/entity/Q43244943

about

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma Molecular biology of high-grade gliomas: what should the clinician know?The molecular biology of WHO grade I astrocytomas IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): histopathologic, immunohistochemical, and genetic studies of four cases.Supratentorial cortical ependymoma: case series and review of the literature.Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas.Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.Molecular pathology of bone tumours: diagnostic implications.EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.1p/19q testing has no significance in the workup of glioblastomas.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies Lentiviral-induced high-grade gliomas in rats: the effects of PDGFB, HRAS-G12V, AKT, and IDH1-R132H.Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery Defective p53 antiangiogenic signaling in glioblastoma.Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers Proximity ligation assay evaluates IDH1R132H presentation in gliomas The future of high-grade glioma: Where we are and where are we going.End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo.A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.How molecular testing can help (and hurt) in the workup of gliomas.Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas.

P2860

Q26995506-476F4C43-E299-4DC6-B6B8-5654BB43AAD3 Q27009190-261CC595-28A2-4D47-89C3-BB9046FDE0E9 Q27010414-A40C0FB8-3968-49C6-99C6-5B65CA0D3EA2 Q27692015-F0EC281F-106D-434C-B2E7-548CDC196C03 Q28066926-D6C9DE41-6405-4B13-94E7-131BB9D4C71D Q28087807-D4F4EA13-6C25-4282-9F7A-CAE6950858CB Q28239475-09F08E8F-62D5-4EBA-AC27-18A0BF4438B5 Q28250795-5AC36583-E537-4075-9590-FF73FA7E8ED1 Q30409080-DB686956-A308-463C-A233-F6C024FE8CAD Q30719284-877EE407-BFCD-4AE4-A034-921618468AD8 Q30810936-18E7C450-2DF3-4236-91EC-781499A84DA7 Q30836702-9B312374-7A73-4770-BBD6-94EDD328D8A6 Q31138637-E96FA428-C6D6-481A-83BF-DE705762A0DC Q33274371-CA540CA5-AF50-4D0B-95C3-BE9328DFD146 Q33275105-36382C8A-2B40-4AF9-BE0C-B8F51CED9872 Q33403967-C21EFF59-7384-499F-8B18-BCF8057984D0 Q33764533-5E323202-82A8-4587-B38D-FF0CD7A105F4 Q33804713-A1EE900C-5BF1-4084-8D18-15941166FFA3 Q33859265-8A6F306E-8EC7-4361-999D-3BDD05E33BF5 Q33893445-AACBCA85-81D1-4F56-AF29-DE65D45BCB8C Q33925544-FB1E9345-7E7B-4E21-975C-3F96A13025D4 Q34000761-4DA1D68D-048E-44DB-8519-1EDE02F2B344 Q34002347-DFE9C882-C934-4F54-AC7A-3DFA6ED06A09 Q34133118-13F9D418-714B-484C-A8F0-295C5A1F525F Q34359670-46AF5A77-72E0-447B-8892-B974986EB9D9 Q34501052-1F291749-2709-4939-B607-93BF33D22209 Q34515911-5C8C8189-FE11-482B-9141-8DA67F5B085B Q34722450-89D9B3BC-EBB7-4510-83B0-D828AB718C3D Q34783220-2FB71523-F502-40C6-8200-47549E830716 Q34815207-0B598486-A09B-4917-8B5E-4258EB188228 Q35056736-C535429D-79EF-437D-A2CF-DC6C88294E6D Q35114090-F4D2EF6A-D192-43BC-998F-EECA5CD9ACF9 Q35149672-89BD6616-CE9A-4C9A-A98C-4D89CDF6EE27 Q35187723-9C6E5977-90C8-4A30-BF40-C475AD1DC1A1 Q35420548-08D8D2D5-6832-4410-9B97-7FF98F53974F Q35751428-6DDE1236-A7BB-4E21-850C-DA6CE3B9D629 Q35770275-F1CC61D7-2176-4884-945E-AF0210A02292 Q35845266-16D5D3D0-51F6-4B71-B795-511DE9FEDC41 Q35920319-5AFF5402-0A0B-4A03-A728-31E1880C52EC Q36124843-BAA5599D-6732-4C47-8176-EDF49A28B1F2

P2860

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

http://www.wikidata.org/entity/Q43244943

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@en

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@nl

type

label

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@en

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@nl

prefLabel

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@en

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@nl

P1433

Q43244943-749FF6CE-D263-44CD-9421-5EBC0ADAF7E0

P1476

Q43244943-9BD26876-AA04-4095-86D1-D2AF3C7E73D5

P2093

Q43244943-008DE5E0-6ED6-4841-B14D-B674561608D8

Q43244943-0F24D7B6-73FE-4935-8B30-256926F3D06E

Q43244943-34E0E249-B9B2-45DC-9F08-DF68E0CD63B3

Q43244943-403C6BAC-C15F-43C5-9A8C-FD6A2E8418DA

Q43244943-4475F871-8626-4302-B14E-99917232AF1B

Q43244943-54246E33-2D52-42BF-BA12-A7C256E1B882

Q43244943-7546A009-1FE8-4342-B6BC-558FF1059BD8

Q43244943-A1D81B92-F46F-45AF-A39B-D89FAE859AD4

Q43244943-A3E2DB6F-965E-4043-BD73-B1A98728ED1F

Q43244943-ACDFB097-BF51-47A6-A9E4-5A0FFA9B1CC3

P304

Q43244943-BD59E0CF-B67B-48F2-A5E7-380792BEA5DD

P31

Q43244943-DE527C61-B71E-4413-A911-D339AF4E1A37

P356

Q43244943-7EABD0D7-9FD1-4915-909F-EBF7D39911DD

P433

Q43244943-FC316C85-69A0-482F-B5D4-04203CF105CE

P478

Q43244943-8CB21274-A7AB-4772-94F2-DA80ED04051C

P50

Q43244943-4AD666F1-C891-412F-815C-AC1EF1352172

Q43244943-52EBAF06-8C72-4198-82CB-B8A7881747D8

P577

Q43244943-78F6286F-84FA-466C-AE50-52E494449199

P5875

Q43244943-C83E81B7-400B-40D0-81B4-E2BB1C743A7B

P698

Q43244943-0C67FD7F-FC74-4345-BB21-D075D1AEFC99

P921

Q43244943-C08C41AB-9B79-440E-B804-1FC8BE9B98FB

P356

J.1750-3639.2009.00352.X

P1433

Brain Pathology

P1476

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

@en

P2093

Andrey Korshunov

http://www.w3.org/2001/XMLSchema#string

Antje Habel

http://www.w3.org/2001/XMLSchema#string

Christian Hartmann

http://www.w3.org/2001/XMLSchema#string

Claudia Tessmer

http://www.w3.org/2001/XMLSchema#string

Diana Jäger

http://www.w3.org/2001/XMLSchema#string

Hanswalter Zentgraf

http://www.w3.org/2001/XMLSchema#string

Jochen Meyer

http://www.w3.org/2001/XMLSchema#string

Jörg Balss

http://www.w3.org/2001/XMLSchema#string

Susanne Weissert

http://www.w3.org/2001/XMLSchema#string

Ulrike Ackermann

http://www.w3.org/2001/XMLSchema#string

P304

245-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1750-3639.2009.00352.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Andreas von Deimling

P577

2009-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38079915

http://www.w3.org/2001/XMLSchema#string

P698

19903171

http://www.w3.org/2001/XMLSchema#string

P921